Cambridge Investment Research Advisors
BTAI icon

Cambridge Investment Research Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,378
Closed -$14K – 3522
2024
Q4 		$14K Hold
2,378
– – ﹤0.01% 3436
2024
Q3 		$23K Hold
2,378
– – ﹤0.01% 3359
2024
Q2 		$49K Hold
2,378
– – ﹤0.01% 3218
2024
Q1 		$107K Hold
2,378
– – ﹤0.01% 3145
2023
Q4 		$112K Buy
+2,378
New +$132K ﹤0.01% 3018
2021
Q4 		– Sell
-459
Closed -$223K – 3180
2021
Q3 		$223K Sell
459
-208
-31% -$91.5K ﹤0.01% 2718
2021
Q2 		$310K Buy
667
+163
+32% +$88.9K ﹤0.01% 2446
2021
Q1 		$348K Buy
504
+148
+42% +$119K ﹤0.01% 2180
2020
Q4 		$263K Sell
356
-25
-7% -$19.5K ﹤0.01% 2254
2020
Q3 		$264K Buy
+381
New +$286K ﹤0.01% 2034

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Cambridge Investment Research Advisors's BTAI Position: Q1 2025 in Review

Cambridge Investment Research Advisors sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2,378 shares — an estimated $14K sold.

Cambridge Investment Research Advisors first reported a position in BTAI in Q3 2020 and held it in 10 quarters. The position peaked at $348K in Q1 2021. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Cambridge Investment Research Advisors reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,378 BioXcel Therapeutics shares in Q1 2025, an estimated $14K.
  • Cambridge Investment Research Advisors first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 10 quarters.
  • Cambridge Investment Research Advisors's BioXcel Therapeutics position peaked at $348K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.